A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Relapsing Multiple Sclerosis, Multiple Sclerosis

In brief

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

Key facts

Study ID

NCT06104683

Run by

Loxo Oncology, Inc.

People needed

0

Starts

2024-05-01

Expected to finish

2026-02-13

Last updated by the study team

2024-03-27

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have been diagnosed with relapsing MS
• Participants must have one of the following
• at least 1 documented relapse within the previous year, or
• at least 2 documented relapse within the previous 2 years, or
• at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

You may not qualify if…

• Have had a diagnosis of primary progressive MS
• Have a history of another clinically significant neurological disease
• Had a relapse of MS within 30 days prior to randomization.

Where it is running

• University of South Florida — Tampa, Florida, United States
• Clinical Trial Network — Houston, Texas, United States
• Swedish Medical Center-501 E Hampden Ave — Seattle, Washington, United States
• Caribbean Center For Clinical Research Inc — Guaynabo, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.